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Summary 
Background Podoconiosis affects an estimated 3 million people in Ethiopia with a further 19 
million at risk. Volcanic soil and pathogens enter skin breaches in the feet causing 
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inflammation, lymphoedema and hyperkeratosis. There is no robust evidence on optimal 
podoconiosis skincare regimens to improve skin barrier function (SBF).  
Objectives To evaluate the effectiveness of a new, low-cost, evidence-based intervention to 
improve SBF in the lower limbs of those with podoconiosis. 
Methods A randomized controlled trial (NCT02839772) was conducted over 3 months in two 
podoconiosis clinics (n = 193). The intervention comprised 2% (v/v) glycerine added to a 
reduced volume of soaking water. The control group received the current skincare regimen. 
Primary outcome measures were transepidermal water loss (TEWL) and stratum corneum 
hydration (SCH) at four specific sites on the lower limbs. 
Results Improvement in SBF was observed in both groups across all measurement sites and 
time points, although this was significantly greater in the experimental group. TEWL reduced 
in both groups at all sites. For example, on top of the foot the estimated group difference in 
TEWL at visit 4 was 1.751 [standard error (SE) = 0.0390] in favour of the experimental 
group [t = 3.15, df = 189.58, P = 0.002, 95% confidence interval (CI) 0.066–2.85], indicating 
a greater reduction in TEWL in the experimental group. Similarly, at the same site the 
estimated group difference in SCH at visit 4 was –2.041 (SE = 0.572) in favour of the 
experimental group (t = –3.56, df = 186.74, P = < 0.001, 95% CI –3.16 to –0.91), indicating 
a greater increase in SCH in the experimental group. There were also significantly greater 
reductions in odour, number of wounds and largest foot circumference in the experimental vs. 
the control group. 
Conclusions The addition of 2% (v/v) glycerol to a reduced volume (83% reduction) of 
soaking water significantly improved SBF. 
 
What’s already known about this topic? 
 Podoconiosis (nonfilarial elephantiasis, sometimes called ‘mossy foot’ due to moss-like 
skin eruptions) is a tropical skin disease caused by irritant soil particles and pathogens 
entering plantar skin via skin breaches, and affects lower leg lymphatics. 
 It is incurable but treatable. 
 The current podoconiosis skincare regimen reduces clinical disease stage and oedema, 
and improves skin condition and quality of life, but may not be optimum and requires 6 L 
of water, a scarce resource. 
 
3 
 
What does this study add? 
 This is the first published randomized controlled trial to evaluate podoconiosis skin 
treatment regimens using quantitative measures of skin barrier function (SBF).  
 A new treatment regimen, incorporating 2% (v/v) glycerol in one-sixth of the current 
water volume, significantly improved SBF and clinical disease presentation compared 
with the current regimen. 
 
Podoconiosis is a non-infectious skin disease that results in bilateral and usually asymmetric 
lymphoedema below the knee.1 It is found in over 20 countries across tropical Africa, Central 
America and northern India.2 Prevalence data, unavailable in most countries, are available in 
Ethiopia. Areas of prevalence are associated with the minerals smectite, mica and quartz 
(crystalline silica) within alkaline volcanic soil.3 Due to poverty or culture, subsistence 
farmers and others may wear no shoes or shoes that give inadequate protection. Plantar 
stratum corneum (SC) thickens, dries and becomes extremely brittle, leading to deep cracks 
and fissures, allowing soil particles and bacteria to enter, triggering the inflammatory 
process.4  
Water is essential to cleanse the skin surface of soil and pathogens, to help maintain healthy 
skin barrier function (SBF) – a major challenge in the developing world, where water is 
typically carried to homes from remote standpipes, wells or rivers. Use of this precious 
resource for washing skin is a relatively low priority, resulting in poor foot hygiene. 
Subsequent oedema disrupts superficial lymphatic drainage, causing further oedema and 
stress on deeper lymphatics. If overloaded, this secondary drainage system can fail, causing 
lymphoedematous feet and legs.5 The high protein content of static lymph fluid in tissues 
leads to trophic skin changes, including hair loss, xerosis, hyperkeratosis, adipose tissue 
deposition and papillomatosis (Fig. 1).6 Figure 2 proposes a cyclical pathogenic model for 
podoconiosis induction and propagation. Without therapeutic intervention, the cycle 
continues, with worsening lymphoedema and skin change. Disease progression has five 
stages of severity (5 = most severe).7 Transforming growth factor beta 1 has a pathogenic role 
in the disease and oxidative stress a lesser role.8 The disease is thought to be T-cell mediated 
with high (63%) heritability.9 
Significant social stigmatization and episodic severe leg pain from adenolymphangitis (ADL) 
give rise to severe macro- and microeconomic effects.10 Acute attacks of ADL cause leg 
inflammation and inguinal lymphadenopathy, which results in lost work days and subsequent 
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loss of family income. The estimated cost in one region of Ethiopia (population 1.5 million) 
was estimated at US$16 million per year. Stigmatization is widespread due to the appearance 
of the disease, unpleasant odour and unfounded fear of infection. Patients report that they are 
unable to marry, are shunned by others and excluded from social events.11 This ostracism 
increases as the disease progresses. Wearing shoes provides only partial protection. One large 
study found heel cracks and foot trauma present regardless of shoe type.12 Therefore, 
maintaining SBF health and effective washing of feet and legs are essential in podoconiosis 
prevention. 
The current treatment regimen taught in the Action on Podoconiosis and Integrated 
Development Organization (APIDO) clinics consists of washing feet and legs daily in soapy 
water, a 30-min soak in 6 L water with 0.0125% (v/v) sodium hypochlorite (NaOCl), air 
drying and application of petrolatum jelly to augment SBF and reduce friction.13 Surfactant 
action removes pathogens/soil, while the soak hydrates the SC (decreasing its elastic 
modulus, thus creating a pliable structure less likely to crack or split) and NaOCl reduces 
pathogen load. Whitfield’s ointment is used, where appropriate, to treat fungal infection. A 1-
year noncomparative longitudinal study using a similar regimen was effective in reducing 
disease clinical stage and oedema, and in improving quality of life scores (n = 27).14 No 
previous randomized controlled trials (RCTs) assessing treatment regimens for this disease 
were identified. 
We hypothesized that addition of low levels of humectant to the regimen would increase SC 
hygroscopicity, thus improving SBF and, ultimately, clinical outcome. Glycerine was chosen 
because of its wide range of efficacy, low cost, and availability even in resource-poor 
settings. In Ethiopia it can be obtained easily in roadside kiosks for around 50 pence per 100 
mL). The chosen glycerol concentration of 2% (v/v) was based on a balance between cost and 
previous studies showing efficacy at this concentration.15–18 Fluhr et al.15 identified glycerol-
related skin benefits as improved SCH, SBF, desmosomal degradation and skin mechanics, 
inhibition of SC lipid-phase transition, accelerated wound healing, reduced irritation and 
some antimicrobial efficacy. To conserve glycerol and water, we reduced the wash-water 
volume by 83%, from 6 L to 1 L. 
 
Materials and methods 
Study design and population 
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The null hypothesis was that an evidence-based skincare intervention that added 2% (v/v) 
glycerol to the current skin regimen used to treat Ethiopian podoconiosis patients would not 
improve SBF and disease-related quality of life, compared with the current regimen. The 
study used an RCT parallel-group design. Data were collected from two APIDO clinics in the 
Gamo Gofa zone, southern Ethiopia, from January to August 2014. Clinics were chosen 
within similar socioeconomic populations and geographical areas (with volcanic soil, high 
rainfall and elevations > 1600 m above sea level). Inclusion criteria were previously untreated 
patients with podoconiosis (determined by the experienced clinic nurses), > 18 years of age 
and able to give informed consent. 
 
Sample size and selection  
Computerized stratification of the sample ensured similar numbers of each sex and of those 
with mild/moderate (stages 1–3) to severe disease (stages 4–5);7 this allowed variance 
between these factors to be determined. The study was powered to detect a difference 
between the treatment groups. Based on the pilot study results,19 an effect size of around 0.72 
was expected for TEWL, the primary outcome measure. To achieve a power of 80% (two-
sided t-test) with a 5% significance level, 64 participants were required, divided equally 
between the two treatment groups. To allow detection of possible smaller effect sizes on 
other secondary outcome measures, a target sample size of 200 was chosen. Participants were 
allocated randomly to groups using a computer-generated sequential system based on clinic, 
sex and disease severity. Randomization was explained to participants as their allocation to a 
group using the current effective treatment or another using an extra, harmless product. Four 
containers were placed in each clinic (labelled by sex/disease severity) containing 
individually-coded sealed opaque envelopes opened sequentially by the nurse to reveal group 
allocation. 
 
Ethical approval 
Ethical approval for the study was obtained from the University of Hull, U.K. (approval letter 
reference 125, 29.11.13) and Sodo University, Ethiopia (24/214/2013). An explanation of the 
study was read out by the clinic nurse to each potential participant and any clarifying 
questions answered. As most were illiterate, those willing to take part signed or marked their 
agreement with a cross or ink mark from their index finger, witnessed, signed and dated by 
the clinic social worker. 
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Study groups and intervention tested 
Each individual was taught (verbally and by demonstration) initially and at each monthly 
visit how to treat their feet/legs according to their group. Control group subjects continued 
with the daily skin treatment used currently in APIDO clinics (see above). In the 
experimental group the treatment was as follows: 1 L water (only) was used for feet soaking 
and splashing lower legs, and 20 mL glycerol was added to provide a 2% (v/v) dilution. 
 
Measures used 
The primary outcome measures of TEWL and SCH were measured using portable, wireless, 
noninvasive probes. TEWL (water flux across the SC, g m–2 h–1) was measured with a 
VapoMeter® closed-chamber evaporimeter (Delfin Technologies, Kuopio, Finland) and SCH 
(reflecting SC water content) was measured in arbitrary units using a MoistureMeter SC 
probe (based on electrical capacitance) (Delfin Technologies). These instruments were used 
previously by one of the authors (P.M.) to successfully measure SBF in those with 
podoconiosis in rural Ethiopia.4 Measurements were taken at three sites: on the outer, lower 
leg (8 cm below the fibula head (top), 8 cm above the external malleolus (base) at the 
midpoint between these sites, and the top of the foot (similar to Ferguson et al.4). 
In each site, SCH measures were made in triplicate (recording the mean). Single TEWL 
measures were recorded. With both of these objective instrumental measurements it is critical 
to minimize interference from environmental artefacts. Therefore, in line with the 
manufacturer’s20 and other published guidelines,21 measurements were restricted to times of 
the day when ambient temperature was lower, and patients were asked to rest and equilibrate 
for at least 20 min with measurement sites exposed. This process was aided by the automatic 
recording of ambient temperature and humidity by the VapoMeter. Measurements of TEWL 
are particularly challenging in external environments. The use of a closed-chamber 
evaporimeter proved to be critical in reducing local atmospheric perturbation and resulting 
measurement noise (as per Ferguson et al.4). 
Other measures recorded were: stage of podoconiosis, trophic changes (mossy/papillomatosis 
changes present/absent); malodour (if detected on foot/leg by clinic nurse); number of 
wounds; work days lost due to ADL (defined as an episode of inflammatory pain associated 
with the lymph nodes within a lymphoedematous leg that led patients to be bedridden/unable 
to work); and largest leg and foot circumferences. The Amharic Dermatology Life Quality 
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Index (ADLQI), which has been validated for assessing those with podoconiosis, was used.22 
Its 10 questions rate aspects of an individual’s disease-related quality of life. The maximum 
score of 3 for each question indicates the disease has a high impact, 2 a lot of impact, 1 a little 
and 0 indicates no impact or the question is irrelevant. 
 
Data collection 
The qualified nurses and social workers who had worked at each clinic for at least 1 year 
received an initial 5-h standardized training session provided by the principal investigator 
(PI). This included practice in measuring the liquids used in the trial, using the instruments 
and completing the data forms under the PI’s supervision. Due to high rates of illiteracy, 
ADLQI questions were read out to individual participants by the clinic nurse. 
A local nurse (with a master’s degree in public health, studying podoconiosis), visited each 
clinic to monitor and review data collection and participant treatment at least seven times 
across the 7-month trial period. The PI also directly monitored staff at each clinic, their 
teaching of participants and data collection at week 1 (each day for 5 days) and then at weeks 
10, 17 and 24. Baseline data were collected prior to intervention (visit 1) and data were then 
collected monthly for three months (visits 2–4). 
 
Data analysis  
The data analysis plan was developed a priori. Data were entered into IBM SPSS 22.0 (IBM, 
Armonk, NY, U.S.A.) and checked for outliers and completeness prior to analysis. Mixed 
multi- level modelling was used for continuous outcome measures. For each such measure, 
the change from baseline at visits 2–4 was calculated and used as the dependent variable in 
the analytic model. Generalized estimating equations were used for discrete, categorical or 
binary outcome measures. For each such measure, the change from baseline at visits 2–4 was 
calculated and used as the dependent variable in the model. The variables controlled for each 
outcome measure model were group, clinic, sex, initial stage of podoconiosis (visit 1), side 
(right/left) of leg and the value of corresponding measures at visit 1. A group-by-time 
interaction was included in the model to allow the group difference, if any, to vary in time. 
 
Results 
Of the 193 participants enrolled onto the study (97 in the control group and 96 in the 
experimental group, all completed except one male control group patient with mild/moderate 
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disease who did not attend visit 4 (see CONSORT flow diagram, Fig. 3). Three participants 
(1.5%) had clinical signs of podoconiosis on only one leg/foot. Legs with clinical signs of 
podoconiosis were used as the unit for analysis (n = 383), except for the analysis of stage of 
podoconiosis where all legs (n = 386) were used as the unit of analysis. Twenty-five 
participants (12.9%) had a different stage of podoconiosis in each leg (moderate/less severe 
vs. severe). No adverse treatment effects were noted. Table 1 provides a demographic profile 
of patients at baseline. 
 
Transepidermal water loss 
Baseline mean TEWL values in both groups were greatest on the top of the foot (weaker 
SBF) and decreased progressively up the lower leg (indicating stronger SBF) (Table 2). Mean 
TEWL values in lower leg/foot sites reduced in both groups at visits 2–4, although the 
reduction was greater in the experimental group (highly significant group difference for all 
leg/foot sites at visit 4) (Table 3, Fig. 4). At all points at visits 2–4 TEWL reduction was 
greater in right legs and highly statistically significant. At the top of the lower leg the 
difference statistics were: t = –3.42, df = 186.089, P = 0.001, 95% CI –0.57 to –0.15; at the 
midpoint: t = –2.59, df = 187.075, P = 0.010, 95% CI –0.65 to –0.087; at the base: t = –2.62, 
df = 189.83, P = 0.010, 95% CI –0.60–0.083; and on the foot: t = –2.57, df = 189.49, P = 
0.01, 95% CI –0.63 to –0.082. 
 
Stratum corneum hydration 
Baseline mean SCH was lower at the base of the leg and top of the foot, increasing 
progressively up the lower leg (Table 4). Mean SCH values at all points on the lower 
legs/feet increased in both groups over visits 2–4, although the increase was greater in the 
experimental group (highly significant) (Table 5, Fig. 5).There was no significant difference 
in SCH between right and left legs except at the base of the lower leg (nearing significance) (t 
= 1.92, df = 180.99, P = 0.057, 95% CI –0.65–0.010). 
 
Stage of podoconiosis of all participants’ legs at baseline and at fourth visit 
At baseline (n = 386), 176 legs (45.6%) displayed severe disease (stages 4–5). By visit 4 (n = 
384), this number had decreased to 50 legs (13.0%). Similarly, at baseline, 207 legs (53.6%) 
displayed mild/moderate disease (stages 1–3). By visit 4, this number had increased to 340 
legs (88.5%). Together, these results indicate clinical improvement due to the two treatment 
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regimens based on the description of stages. There was no significant treatment group 
difference at visit 4 [log odds ratio (OR) 0.45, standard error (SE) = 0.26; Wald  = 3.14, df 
= 1, P = 0.076, 95% CI –0.048–0.95] nor stage difference between right/left legs. 
 
Trophic (‘mossy’) skin changes  
At baseline, trophic skin changes were present in 153 (79.3%) right legs/feet and in 156 
(80.8%) left legs/feet. By visit 4, trophic changes were reduced and present in 120 (62.5%) 
right legs/feet and 117 (60.9%) left legs/feet: however, there was neither a significant 
treatment group difference at visit 4 nor between right/left legs. 
 
Odour 
At baseline, odour was present in 114 (59.1%) of legs/feet. By visit 4, odour was reduced and 
present in only two right legs/feet (1%) and one left leg/foot (0.5%). The odds of leg odour 
being present at visits 2, 3 and 4 were significantly lower in the experimental group (log OR 
–0.866, SE = 0.401; Wald 2 = 4.67, df = 1, P = 0.031, 95% CI –1.652 to –0.080). However, 
the group difference was not clinically significant because the numbers with leg odour in 
each group reduced to almost zero. 
 
Number of wounds 
At baseline, 105 participants (54.4%) had four wounds (all were skin breaches and all areas 
of fungal infection were on the legs/feet). The experimental treatment led to significantly 
fewer wounds on legs/feet at visits 2–4 (for group difference P < 0.05). Those in the 
experimental group were expected to have fewer wounds (group ratio estimate = 2.06, SE = 
0.74; Wald 2 = 7.75, df = 1, P = 0.005, 95% CI 0.61–3.51). As most participants at visit 4 
had no wounds, the group difference was clinically insignificant. 
 
Number of days of work lost in previous month due to adenolymphangitis 
At baseline, the mean number of work days lost in the previous month due to ADL was 4.56 
for the control group and 4.44 for the experimental group. The group ratio in the expected 
number of days lost at visit 4 was not significant (group ratio estimate = 2.09, SE = 1.10; df = 
1, P = 0.058, 95% CI –0.069–4.25), nor was the difference clinically significant as no 
participants lost any work days in the previous month due to ADL. 
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Correlation between days lost due to adenolymphangitis and number of wounds  
The Spearman rank correlation coefficient at baseline was 0.25, at the second visit 0.31, the 
third 0.29 and the fourth 0.27. This indicated that at all time points there was a weak but 
highly significant correlation (P < 0.001) between the number of lower leg/foot wounds 
totalled over both legs and the number of days participants were unable to work due to ADL 
for visits 2, 3 and 4. 
 
Largest lower leg circumference 
In the control group the largest lower leg circumference reduced over the study period by 3.8 
cm (from 32.1 to 28.3cm) and in the experimental group by 4.2 cm (32.0 to 27.8 cm). The 
between-group treatment difference was not significant (t = 1.42, df = 185.39, P = 0.16, 95% 
CI –0.11–0.69). 
 
Largest foot circumference 
In the control group, the mean foot circumference reduced over the study period by 2.4 cm 
(from 27.5 to 25.1 cm). The reduction was greater in the experimental group by 3 cm, (from 
27.7 to 24.7 cm). The treatment group difference was highly statistically significant (t = 3.55, 
df = 169.92, P < 0.001, 95% CI 0.26–0.89). The reduction in circumference was significantly 
greater in the right foot (t = –3.27, df = 152.99, P = 0.001, 95% CI –0.24–0.059). 
 
Amharic Dermatology Life Quality Index 
The mean ADLQI reduced in both groups over the study period, indicating an improved self-
assessed disease-related quality of life. In the control group, the mean ADLQI reduced from 
21.6 to 4.1 (an improvement of 17.5 points). In the experimental group, the mean ADLQI 
reduced from 21.1 to 3.9 (an improvement of 17.2 points). The estimated group difference at 
visit 4 was not statistically significant (t = –0.12, df = 178.81, P = 0.90, 95% CI (–1.13–
1.002). 
 
Discussion 
To our knowledge, this is the first RCT to study podoconiosis skincare regimens, and the 
largest to use a dilution of only 2% glycerol to improve SBF. As hypothesized, the addition 
of 2% (v/v) glycerol to a significantly reduced volume of soaking water led to significant 
incremental improvements in SBF in the lower legs and feet of those with podoconiosis. This 
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was evident in the significantly higher recorded values of SCH and lower recorded values of 
TEWL in skin on legs and feet of those receiving the experimental vs. the current treatment 
regimen. This was accompanied by significantly greater reductions in malodour, number of 
wounds and largest circumference of foot in the experimental group vs. the control group. No 
adverse effects were reported. 
Ferguson et al.4 measured SBF in those with podoconiosis vs. matched control subjects in a 
previous non-intervention study. They reported significantly lower levels of SCH in the 
feet/lower legs of those with podoconiosis, indicating a greater propensity to SC dryness and 
cracking for those with the disease (hence, a higher risk of reactive soil/pathogens entering 
foot tissue). This current study builds on these insights and demonstrates conclusively the 
central role of compromised SBF in the induction and propagation of podoconiosis. There is 
no other explanation for the relatively acute significant effect of only 2% (v/v) glycerol, in a 
simple water soak, on both objective SBF measures and clinical outcome in this chronic 
lymphoedematous condition. 
We propose a therapeutic model centred around increasing SC hygroscopicity and on the 
cascade of ensuing events, summarized by Rawlings and Matts,23 including: (i) an immediate 
reduction in the SC elastic modulus, resulting in a softer, more flexible substrate less prone to 
cracking/splitting; (ii) longevity of SCH, activating desquamatory enzymes in previously dry 
SC, leading to a significantly thinner, more compact SC over time; (iii) a reduction in the 
inflammatory process, leading to a more mature, efficient SC; and (iv) ultimately, restoration 
of healthy SBF, better able to prevent ingress of irritant soil/pathogens into tissue. 
Sikorski et al.14 investigated the effect of a similar skin hygiene regimen in patients with 
podoconiosis vs. a control group over 1 year. Despite the current study being only 3 months 
in duration, we report higher reductions in largest lower leg circumference (4.0 cm and 4.1 
cm, respectively, in this study vs. 2.0 cm for Sikorski et al.14) and a greater improvement in 
ADLQI score (17.1 and 17.5 points, respectively, in this study vs. 15.0 for Sikorski et al.14). 
We cannot account for these differences in response but hypothesize that there could be 
different study populations, locations, climate or skin regimen compliance. 
In this current 3-month intervention study, 62.7% of legs/feet still had ‘mossy’ trophic 
changes evident across the treatment groups, compared with 22.2% reported by Sikorski et al. 
after 1 year of treatment.14 This indicates that a longer period of continuous treatment is 
probably needed to reduce trophic changes. It is remarkable that an intervention comprising 
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water, soap and petrolatum can bring about these improvements at all and, once again, 
indicates the importance of improving and maintaining SBF in the treatment regimen. 
In this study, a reduction in the number of wounds in both groups was associated with a 
reduction in the work days lost due to ADL. This is important, as most of those in this study 
were subsistence farmers, so any income loss would have significant economic effects. 
Indeed, it is estimated that Ethiopia loses approximately US$200 million annually through 
lost work days due to podoconiosis.10 
The current study and that of Sikorski et al.14 both demonstrate the utility of simple treatment 
regimens in significantly improving quality of life in those with podoconiosis (evidenced by 
improved DLQI scores). We hypothesize that this is likely due to a combination of the 
skincare and attention received in treatment sites, the visible improvement in leg/foot 
condition, reduction in ADL and odour, and a concomitant decrease in stigma and ostracism. 
The significant difference in TEWL reduction in right vs. left legs and greater reduction in 
circumference of the right foot may have been due to more attention being given to the right 
leg during treatment or to this leg being used more than the left when walking (in those with a 
right-side preference). Exercise is known to improve circulation and venous return, thus 
reducing oedema.6 It could also be explained by anatomical and physiological differences 
between legs that impair left leg venous and lymphatic drainage.25 
Finally, in this study, we incorporated 2.0% (v/v) glycerol into only 1 L of wash/soaking 
water (vs. the current 6 L). Participants were able to follow instructions and use the new 
treatment protocol effectively. This new regimen not only conserves the precious resource of 
water, but also minimizes glycerol requirement. 
In summary, the results of this study support our hypothesis that current podoconiosis 
treatment regimens can be enhanced further by increasing the water-binding potential of the 
SC with the humectant, glycerol, which is widely available in Ethiopia, even in rural settings, 
at low cost. The addition of glycerol to a water soak may be effective in a wide variety of 
other skin diseases, including lymphoedematous conditions such as lymphatic filariasis, 
where compromised SBF is indicated and skincare is critical. Glycerine use in podoconiosis 
treatment is currently being considered for implementation by APIDO. Further research is 
needed to investigate lower dilutions of glycerol and different soaking methods (e.g. 
wrapping technique) to further reduce cost and water usage, and increase efficiency. 
There are some study limitations: Podoconiosis diagnosis was based on participants living at 
high altitude, with volcanic soil, high rainfall, and with clinical manifestations of the disease. 
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No differential diagnosis was made to exclude those with swelling of the lower leg due to 
other diseases such as lymphatic filariasis, liver or heart failure. Although groups were 
matched as far as possible, there may have been other confounding factors influencing the 
results that are not identified. Although participants were not supervised daily to ensure 
treatment adherence, improvements in SBF would not have been achieved without some level 
of compliance. 
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Figure legends 
Fig 1. Feet of patients presenting with oedema, hyperkeratosis, nodules, fused toes, mossy 
changes and ulceration due to ill-fitting shoes. 
Fig 2. Development and cycle of progression of lymphoedema in podoconiosis. 
Fig 3. CONSORT 2010 flow diagram. 
Fig 4. Top of foot: difference over time between groups in mean transepidermal water loss (g 
m–2 h–1). 
Fig 5. Top of foot: difference over time between groups in mean stratum corneum hydration 
(arbitrary units). 
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Table 1 Demographic profile of all participants at baseline (n = 193) 
Age 
(years) 
n (%) Occupation n (%) Time to 
onset 
(years) 
n (%) Shoes worn in previous 
week  
n (%) 
18–29 54 (28) Farmers 89 (46.1) > 1 2 (1) Barefoot 18 (9.4) 
30–39 33 (15.8) Housewives 82 (42.5) 1–2 47 (24.4) Hard plastic sandals 120 (62.2) 
40–49 47 (22.5) Students 14 (7.3) 3–4 49 (25.4) Canvas shoes 24 (12.4) 
50–59 32 (15.3) Others, e.g. 
servants and 
merchants  
8 (4.1) 5–6 47 (24.4) Other enclosed shoes 20 (10.4) 
60–69 22 (10.5)   7–8 23 (11.9) Open sandals made with 
tyres 
9 (4.7) 
> 70 5 (2.6)   9–10 18 (9.3) Other sandals 2 (1) 
    11–12 4 (2.1)   
    > 12 3 (1.6)   
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Table 2 Mean transepidermal water loss (TEWL) across all participants measured at different 
anatomical sites within podoconiosis-affected legs/feet, at baseline 
Site on the lower leg Mean TEWL right leg, first visit Mean TEWL left leg, first visit 
Top 13.08 13.40 
Midpoint 14.29 15.02 
Base 16.62 17.17 
Top of foot 22.41 22.75 
All data are presented in g m–2 h–1. 
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Table 3 Estimated group differences in transepidermal water loss (TEWL) at visits 2, 3 and 4 
Anatomical site  Estimated group difference in 
TEWL (g m–2 h–1) 
SE t df P 95% CI for the group 
difference 
Top of outer lower leg 1.58 0.30 5.34 89.35 < 0.001  0.10–2.16 
Midpoint of outer lower leg 1.68 0.35 4.87 189.79 < 0.001 1.002–2.37 
Base of outer lower leg 1.97 0.39 5.11 189.62 < 0.001 1.21–2.73 
Middle of top of foot  1.75 0.39 3.15 189.58 0.002 0.66–2.85 
SE, standard error; df, degrees of freedom; CI, confidence interval. 
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Table 4 Mean stratum corneum hydration (SCH) across all participants measured at different 
anatomical sites within podoconiosis-affected legs/feet at baseline 
Site on the lower leg Mean SCH, right lower leg Mean SCH, left lower leg 
Top  9.33 9.54 
Midpoint 9.03 9.23 
Base 8.51 8.55 
Top of foot  8.49 8.62 
All data are presented in arbitrary units, measured using the MoistureMeter (Delfin 
Technologies, Kuopio, Finland). 
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Table 5 Estimated group differences in stratum corneum hydration at visits 2, 3 and 4 
Site on the lower 
outer leg 
Estimated group 
difference 
SE t df P 95% CI for the group 
difference 
Top –2.08 0.52 –4.24 165.31 < 0.001 –3.04 to –1.11 
Midpoint –1.66 0.47 3.55 180.92 < 0.001 –2.58 to –0.74 
Base –1.64 0.47 – 3.47 186.31 0.001 –2.57 to –0.71 
Top of foot  –2.04 0.57 –3.57 186.74 < 0.001 –3.17 to –0.91 
All data are presented in arbitrary units. SE, standard error; df, degrees of freedom; CI, 
confidence interval. 
